Skip to Content
About Abbott
Contact
United States | eng
Country Language
CARDIOVASCULAR
United States | eng
Country Language

Gallant HF

Cardiac Resynchronization Therapy Defibrillator (CRT-D)

Gallant HF next to a phone displaying the phone app on top of a gradient background
Clinical Evidence
Join Our Email List

Clinical Evidence

Advanced CRT Optimization

Every patient deserves life-changing therapy. Abbott's next generation CRT-D solutions make it possible for you to achieve clinically meaningful outcomes:

100% of patients had a narrower QRS when SyncAV™ CRT technology was optimized1

  • CRT-induced QRS narrowing has been shown to improve clinical outcomes for heart failure patients2,3

22% fewer heart failure hospitalizations for patients with SyncAV CRT technology enabled vs. patients with the technology disabled4

87% response rate shown in IDE study subgroup with anatomically programmed separation using MultiPoint™ pacing5

  • In a separate study, MultiPoint pacing led to significantly more responders and fewer non-responders vs. biventricular pacing (p < 0.05)6

Stay Informed

Sign up to hear about our technology, education opportunities, and more.

Join Our Email List

Read the Latest Blog Article

Stay up to date with recent news, product highlights, and case studies.

Visit the Abbott CRM Blog

Manuals & Technical Resources

Reimbursement & Coding

Customer Service

References

  1. Varma N, O’Donnell D, Bassiouny M, et al. Programming cardiac resynchronization therapy for electrical synchrony: reaching beyond left bundle branch block and left ventricular activation delay. J Am Heart Assoc. 2018;7:e007489. https://www.ahajournals.org/doi/10.1161/JAHA.117.007489. Accessed January 14, 2020.
  2. Canadian Cardiovascular Society. Clinical Significance of Electromechanical Dyssynchrony and QRS Narrowing in Patients With Heart Failure Receiving Cardiac Resynchronization Therapy. https://doi.org/10.1016/j.cjca.2018.10.019. Accessed February 25, 2019.
  3. Okafor O, Leyva F, Zegard A, et al. Changes in QRS Area and QRS Duration After Cardiac Resynchronization Therapy Predict Cardiac Mortality, Heart Failure Hospitalizations, and Ventricular Arrhythmias. J Am Heart Assoc. 2019;8:e013539. DOI:10.1161/JAHA.119.013539.
  4. Varma, N., Gain in CRT Efficacy with Dynamic Electrical Optimization: Real World Effect of SyncAV™ CRT on Heart Failure Hospitalizations. Poster presented at EHRA. May 2020. https://esc365.escardio.org/home. Accessed May 15, 2020.
  5. Niazi, et al. Safety and efficacy of multipoint pacing in cardiac resynchronization therapy—the multipoint pacing trial. JACC: Clinical Electrophysiology. Volume 3, Issue 13, 26 December 2017, Pages 1519-1522. https://doi.org/10.1016/j.jacep.2017.06.022. Accessed January 14, 2020.
  6. Musaad AMA, Bokhari F, Sweidan R, et al. Long term effect of MultiPoint Pacing in Heart Failure patients on end systolic volume: preliminary results from a randomized and multicenter study in the Middle East. APHRS presentation, 2019.

MAT-2007536 v4.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
abbott logo

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2024 Abbott. All Rights Reserved.

MAT-1900882 v13.0